ClinicalTrials.gov
ClinicalTrials.gov Menu

Brainstem Dysfunction Involvement in the Pathogenesis of Pierre Robin Sequence (DYSROBIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03423017
Recruitment Status : Recruiting
First Posted : February 6, 2018
Last Update Posted : May 31, 2018
Sponsor:
Information provided by (Responsible Party):
Hospices Civils de Lyon

Brief Summary:

Introduction Pierre Robin Sequence, PRS, incidence is about one hundred births per year in France. The main neonatal clinical manifestations are secondary to airway obstruction and food difficulties related to swallowing disorders. Despite recent progress, the pathogenesis of PRS is not fully understood.

The hypothesis is that brainstem dysfunction, BSD, plays a central role in the pathogenesis of PRS.

The purpose of the study is to achieve a complete evaluation of BSD to specify its role in the pathogenesis of PRS.

The primary objective is to compare central apnea index (CAI) of infants with PRS with those of infants with isolated airway obstruction (AWO) and those of healthy infants in order to clarify the direct role of BSD.

Material and Methods This prospective interventional study will be carried out in Lyon at the Hôpital Femme-Mère-Enfant and in Paris at the Hôpital Necker-Enfants Malades for 2 years. 3 groups of patients will be studied: PRS, 50 patients, AWO, 50 patients and healthy, 30 patients, included before 2 months of life. Infants will be followed for a maximum of 10 months. The evaluations will be carried out for 48 hours between birth and 2 months of life and then for 24 hours between 6 and 10 months of life for PRS and AWO group. Concerning the healthy group, the evaluation will be carried out during 48h during a single hospitalization before 2 months. Polysomnography, holter-ECG, 24h gas exchange, impedance-pH monitoring and mental region EEG will be performed. The central apnea index (mean number per hour), obstructive apnea index, non-nutritive swallowing index (NNS), gastroesophageal reflux and NNS-respiration coordination will be assessed for each stage of sleep and compared between the three groups of patients.


Condition or disease Intervention/treatment Phase
Pierre Robin Sequence Brainstem Dysfunction Other: Recording of data Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 130 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Brainstem Dysfunction Involvement in the Pathogenesis of Pierre Robin Sequence
Actual Study Start Date : May 28, 2018
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : December 2020


Arm Intervention/treatment
Pierre Robin sequence

Infants with PRS : retrognathism, glossoptosis, cleft palate

Group 1a : isolated PRS Group 1b : PRS with bone disease or collagen disease (Stickler) Group 1c : syndromic PRS or associated PRS without bone disease or collagen disease

Other: Recording of data

Recording during one hospitalization of 48 hours between birth and 2 months of life and one hospitalization of 24 hours between 6 and 10 months of life

  • General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs : first and second visit
  • Respiratory rate, respiratory signs, stridor : first and second visit
  • 24h holter-ECG : first and second visit
  • 24h impedance pH-metry : first visit
  • Nocturne polysomnography : 50% prone position, 50% supine : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram) : first and second visit
  • 24 h gaz exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index : first and second visit

Superior airway obstruction, AWO
Infants with AWO : laryngomalacia, tracheal stenosis, laryngeal stenosis, others etiology
Other: Recording of data

Recording during one hospitalization of 48 hours between birth and 2 months of life and one hospitalization of 24 hours between 6 and 10 months of life

  • General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs : first and second visit
  • Respiratory rate, respiratory signs, stridor : first and second visit
  • 24h holter-ECG : first and second visit
  • 24h impedance pH-metry : first visit
  • Nocturne polysomnography : 50% prone position, 50% supine : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram) : first and second visit
  • 24 h gaz exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index : first and second visit

Healthy infants
Healthy infants : siblings of sudden unexpected death of the infant
Other: Recording of data

Recording during one hospitalization of 48 hours between birth and 2 months of life

  • General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs
  • Respiratory rate, respiratory signs, stridor
  • 24h holter-ECG
  • 24h impedance pH-metry
  • Nocturne polysomnography : 100% supine position : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram)
  • 24 h gas exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index




Primary Outcome Measures :
  1. Central apnea index (CAI) (mean number per hour) [ Time Frame: 2 months of life during one nocturne polysomnography ]

    To compare central apnea index (CAI) (mean number per hour), according to the ASSM guidelines 2007, recording by one nocturne polysomnography, between 3 groups of infants by sleep step, between birth and 2 months of life, in order to clarify the direct role of BSD.

    According to the ASSM guidelines 2007, the central apnea index is measured : mean number of central apnea per hour.



Secondary Outcome Measures :
  1. Obstructive apnea hypopnea index (OAHI)(mean number per hour) [ Time Frame: 2 months ]
    To compare obstructive apnea hypopnea index (OAHI)(mean number per hour) according to the guidelines ASSM 2007, recording by one nocturne polysomnography, between 3 groups of infants by sleep step, between birth and 2 months of life According to the ASSM guidelines 2007, the obstructive apnea hypopnea index is measured: mean number of obstructive apnea and hypopnea per hour.

  2. Comparison of OAHI(mean number per hour) and CAI [ Time Frame: between 6 and 10 months of life ]

    To compare obstructive apnea hypopnea index (OAHI)(mean number per hour) and central apnea index (CAI) (mean number per hour), between PRS group and AWO group by sleep step between 6 and 10 months of life

    According to the ASSM guidelines 2007, the obstructive apnea hypopnea index, mean number of obstructive apnea and hypopnea per hour, and the central apnea index are measured, mean number of central apnea per hour.


  3. Micro arousals index (mean number per hour) [ Time Frame: up to 2 months of life ]

    To compare micro arousals index (mean number per hour) between the 3 groups by sleep step between birth and 2 months of life and between PRS group and AWO group between 6 and 10 months of life to clarify the role of BSD in sleep microstructure

    According to the ASSM guidelines 2007, micro arousals index (mean number per hour) are measured.


  4. Micro arousals index (mean number per hour) [ Time Frame: up to 10 months of life ]

    To compare micro arousals index (mean number per hour) between the 3 groups by sleep step between birth and 2 months of life and between PRS group and AWO group between 6 and 10 months of life to clarify the role of BSD in sleep microstructure

    According to the ASSM guidelines 2007, micro arousals index (mean number per hour) are measured.


  5. Non-nutritive swallowing index (NNS) and apnea secondary to non-nutritive swallowing [ Time Frame: up to 2 months of life ]

    To compare non-nutritive swallowing index (NNS) and apnea secondary to non-nutritive swallowing between the 3 groups by sleep step between birth and 2 months of life and between PRS group and AWO group between 6 and 10 months of life to clarify the role of BSD in swallowing disorders and NNS-respiration coordination

    non-nutritive swallowing index (NNS), mean number per hour, and apnea secondary to non-nutritive swallowing, mean number per hour, monitoring by the mental region EEG and the one nocturne polysomnography


  6. Non-nutritive swallowing index (NNS) and apnea secondary to non-nutritive swallowing [ Time Frame: up to 10 months of life ]

    To compare non-nutritive swallowing index (NNS) and apnea secondary to non-nutritive swallowing between the 3 groups by sleep step between birth and 2 months of life and between PRS group and AWO group between 6 and 10 months of life to clarify the role of BSD in swallowing disorders and NNS-respiration coordination

    non-nutritive swallowing index (NNS), mean number per hour, and apnea secondary to non-nutritive swallowing, mean number per hour, monitoring by the mental region EEG and the one nocturne polysomnography




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 2 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria for the group 1

- infants with PRS

Inclusion Criteria for the group 2 - infant with isolated airway obstruction

Inclusion Criteria for the group

- healthy infant : siblings of sudden unexpected death of the infant

Inclusion Criteria for the 3 groups

  • During one hospitalization or program for one hospitalization
  • Parental consent
  • Social safety affiliation

Exclusion Criteria:

  • Birth before 37 SA
  • Neonatal complication
  • Group 2 only: AWO with neurological disease including brainstem dysfunction
  • Group 3 only : AWO, ENT disease or syndromic disease, neurological disease including brainstem dysfunction, Intra uterine growth retardation, antenatal smoking

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03423017


Contacts
Contact: Philippe REIX, Pr 4 72 12 94 37 ext +33 phlippe.reix@chu-lyon.fr
Contact: Lauriane Couturier 4 27 85 59 69 ext +33 lauriane.couturier@chu-lyon.fr

Locations
France
Hopital Femme Mère Enfant Recruiting
Bron, France, 69500
Contact: Philippe REIX, MD PhD    4 72 12 94 37 ext +33    philippe.reix@chu-lyon.fr   
Contact: Laurianne COUTIER, MD    4 27 85 59 69 ext +33    lauriane.coutier@chu-lyon.fr   
APHP-Necker Not yet recruiting
Paris, France, 75015 Paris
Contact: Brigitte Fauroux, MD PhD    171196321 ext +33    brigitte.fauroux@aphp.fr   
Sponsors and Collaborators
Hospices Civils de Lyon

Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT03423017     History of Changes
Other Study ID Numbers: 69HCL17_0816
First Posted: February 6, 2018    Key Record Dates
Last Update Posted: May 31, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Hospices Civils de Lyon:
Pierre Robin sequence
Brainstem
pathogenesis
swallowing
apnea

Additional relevant MeSH terms:
Pierre Robin Syndrome
Jaw Abnormalities
Jaw Diseases
Musculoskeletal Diseases
Maxillofacial Abnormalities
Craniofacial Abnormalities
Musculoskeletal Abnormalities
Stomatognathic Diseases
Stomatognathic System Abnormalities
Congenital Abnormalities